Eli Lilly (LLY) FCF Margin (2009 - 2026)
Eli Lilly posted quarterly FCF Margin of 15.19% for Q1 2026, up 1396.0% year-on-year from 1.02% in Q1 2025, and up 332.22% on a QoQ basis from 3.51% in Q4 2025.
Eli Lilly (LLY) has 18 years of FCF Margin data on file, last reported at 15.19% in Q1 2026.
- For the quarter ending Q1 2026, FCF Margin rose 1396.0% year-over-year to 15.19%; the trailing twelve-month figure through Mar 2026 stood at 16.36% (up 874.0% YoY), and the FY2025 full-year result was 13.77%, up 542.0% from the prior year.
- FCF Margin for Q1 2026 stood at 15.19%, up from 3.51% in the prior quarter.
- Across five years, FCF Margin topped out at 38.34% in Q3 2025 and bottomed at 14.79% in Q4 2023.
- The 5-year median for FCF Margin is 12.52% (2022), against an average of 11.2%.
- The widest annual swing landed in 2023, when FCF Margin slumped 3070 bps; it then jumped 2201 bps in 2024.
- A 5-year view of FCF Margin shows it stood at 15.91% in 2022, then tumbled by 193 bps to 14.79% in 2023, then soared by 149 bps to 7.22% in 2024, then slumped by 51 bps to 3.51% in 2025, then surged by 332 bps to 15.19% in 2026.
- The last three FCF Margin figures came in at 15.19% (Q1 2026), 3.51% (Q4 2025), and 38.34% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 15.19% |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 6.09% |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 23.76% |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 17.97% |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 17.14% |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 34.87% |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 93.16% |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 6.59% |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.19% |
| Dec 31, 2025 | 3.51% |
| Sep 30, 2025 | 38.34% |
| Jun 30, 2025 | 8.93% |
| Mar 31, 2025 | 1.23% |
| Dec 31, 2024 | 7.22% |
| Sep 30, 2024 | 20.64% |
| Jun 30, 2024 | 2.14% |
| Mar 31, 2024 | 2.05% |
| Dec 31, 2023 | -14.79% |
| Sep 30, 2023 | 12.84% |
| Jun 30, 2023 | -1.28% |
| Mar 31, 2023 | 15.26% |
| Dec 31, 2022 | 15.91% |
| Sep 30, 2022 | 23.04% |
| Jun 30, 2022 | 12.52% |
| Mar 31, 2022 | 27.63% |
| Dec 31, 2021 | 24.63% |
| Sep 30, 2021 | 19.11% |
| Jun 30, 2021 | 20.69% |
| Mar 31, 2021 | 20.53% |
| Dec 31, 2020 | 18.29% |
| Sep 30, 2020 | 24.62% |
| Jun 30, 2020 | 40.25% |
| Mar 31, 2020 | 2.12% |
| Dec 31, 2019 | 26.78% |
| Sep 30, 2019 | 22.76% |
| Jun 30, 2019 | 14.39% |
| Mar 31, 2019 | 2.11% |
| Dec 31, 2018 | 18.70% |
| Sep 30, 2018 | 34.90% |
| Jun 30, 2018 | 21.62% |
| Mar 31, 2018 | 4.03% |
| Dec 31, 2017 | 21.10% |
| Sep 30, 2017 | 28.96% |
| Jun 30, 2017 | 24.54% |
| Mar 31, 2017 | 3.27% |
| Dec 31, 2016 | 27.72% |
| Sep 30, 2016 | 27.62% |
| Jun 30, 2016 | 21.40% |
| Mar 31, 2016 | -7.68% |
| Dec 31, 2015 | 11.46% |
| Sep 30, 2015 | 16.76% |
| Jun 30, 2015 | 14.56% |
| Mar 31, 2015 | -5.89% |
| Dec 31, 2014 | 20.15% |
| Sep 30, 2014 | 28.60% |
| Jun 30, 2014 | 16.19% |
| Mar 31, 2014 | 1.50% |
| Dec 31, 2013 | 21.74% |
| Sep 30, 2013 | 30.10% |
| Jun 30, 2013 | 25.31% |
| Mar 31, 2013 | 3.95% |
| Dec 31, 2012 | 19.96% |
| Sep 30, 2012 | 25.03% |
| Jun 30, 2012 | 20.11% |
| Mar 31, 2012 | 12.88% |
| Dec 31, 2011 | 27.93% |
| Sep 30, 2011 | 30.87% |
| Jun 30, 2011 | 30.41% |
| Mar 31, 2011 | 18.40% |
| Dec 31, 2010 | 31.96% |
| Sep 30, 2010 | 29.07% |
| Jun 30, 2010 | 31.44% |
| Mar 31, 2010 | 15.18% |
| Dec 31, 2009 | 29.69% |
| Sep 30, 2009 | 21.01% |
| Jun 30, 2009 | 14.10% |
| Mar 31, 2009 | -1.37% |